Cell derived microparticles: method development, and clinical and experimental studies by Mobarrez, Fariborz
	  Institutionen för kliniska vetenskaper  
Danderyds sjukhus 
 
CELL DERIVED MICROPARTICLES: 
METHOD DEVELOPMENT, AND CLINICAL 
AND EXPERIMENTAL STUDIES 
AKADEMISK AVHANDLING 
som för avläggande av medicine doktorsexamen vid Karolinska 
Institutet offentligen försvaras i Aulan, Danderyds sjukhus, entréplan 
 
Fredagen den 8 mars 2013, kl 09.00 
av 
Fariborz Mobarrez 
 
Huvudhandledare:  
Docent Håkan Wallén  
Karolinska Institutet  
Institutionen för kliniska vetenskaper,  
Danderyds Sjukhus  
Enheten för kardiovaskulär medicin 
	  
Bihandledare:	   
Docent Jovan Antovic 
Karolinska Institutet  
Institutionen för molekylär medicin och kirurgi 
Enheten för klinisk kemi, 
Karolinska Universitets Sjukhuset, Solna 
 
Docent Nils Egberg 
Karolinska Institutet  
Institutionen för molekylär medicin och kirurgi 
Enheten för klinisk kemi, 
Karolinska Universitets Sjukhuset, Solna	  
Fakultetsopponent:	  
Prof. Alison Goodall 
Department of Cardiovascular Sciences, 
University of Leicester, UK 
	  
Betygsnämnd:	  
Docent Angela Silveira 
Karolinska Institutet 
Institutionen för medicin, Solna 
Enheten för aterosklerosforskning  
 
Docent Anders Gottsäter 
Kärlkliniken 
Skånes universitetssjukhus, Malmö 
 
Prof. Tomas Lindahl 
Linköpings Universitet 
Institutionen för klinisk och experimentell medicin 
Klinisk kemi 
Stockholm 2013 
 
ABSTRACT 
Background 
Cell derived microparticles (MP) are released from the cell membrane upon activation or apoptosis. They 
resemble their parent cell by exposing similar proteins or surface receptors. This enables identification of 
their cellular origin. MP are considered to facilitate cross-talk between cells, and to be involved in 
coagulation, inflammation and vascular function. Elevated circulating MP have been shown in previous 
studies. Assessment of MP is, however, difficult due to methodological issues.  
 
Aims 
To evaluate pre-analytical procedures and a flow cytometric method for detection of microparticles. To 
study the effects of statin treatment and inflammation on phenotype and functional properties of 
microparticles.   
 
Methods and Results 
In Paper I we describe a flow cytometric method for measurements of platelet derived microparticles 
(PMP) exposing CD62P or CD142. Mean fluorescence intensity measurements were more reproducible 
than concentration measurements. The presence of platelet fragments could be detected with the peptide 
phalloidin. This approach can be used as a quality control of samples. Samples frozen and stored as 
platelet-free plasma generated lowest number of platelet fragments upon flow cytometric analysis. Using 
our flow cytometric protocol we found two times higher exposure of CD62P and CD142 on PMP in plasma 
from type 1-diabetes patients compared to healthy controls.  
 
In Paper II and III we investigated the effects of atorvastatin on MP. Nineteen patients with 
atherothrombotic disease were randomized to treatment with atorvastatin or placebo in a cross-over fashion. 
Thrombin generation and exposure of CD61, CD62P, CD142 and phosphatidylserine (PS) were assessed on 
PMP (Paper II). Endothelial derived MP (EMP) were assessed by CD144 or CD144+ CD142+ exposure 
(Paper III). During atorvastatin treatment both thrombin generation and exposure of CD61, CD62P, and 
CD142 on PMP decreased. No effect was seen on PS exposure. Furthermore, we demonstrated that MP 
enhanced thrombin generation through PS and CD142 exposure. Unexpectedly, circulating EMP measured 
as CD144 or CD144+ CD142+ increased significantly during atorvastatin treatment. 
 
In Paper IV we investigated and characterized in vivo release of MP from 15 healthy volunteers 
administered lipopolysaccharide (LPS) in the presence of hydrocortisone with or without inhaled nitric 
oxide. MP from platelets (CD42a or CD41), endothelial cells (CD144 or CD62E) and monocytes (CD14) 
were studied. Nuclear content in MP was assessed (SYTO 13 binding) as well as HMGB1 exposure. 
Irrespective of treatment, LPS led to an increase in numbers of all MP, as well as the number of PMP and 
monocyte MP positive for anti-HMGB1 and SYTO 13.  
 
Conclusions 
We describe a flow cytometric method to measure MP in plasma, and we demonstrate that MP from 
platelets and endothelial cells respond differently to statin treatment, reflecting the complexity of MP 
formation. Furthermore, we show that experimental inflammation leads to elevated circulating MP, and that 
MP may be a source of extracellular HMGB1. MP may be used as biomarkers, an idea that deserves to be 
investigated more extensively in future studies. 
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